Immunodominant acetylcholine receptor alpha subunit peptide: MHC complexes
AssigneeCorixa Corporation
InventorsEdward Spack, Subhashini Arimilli, Shrikant Deshpande, Nancy Wehner
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the treatment of autoimmune diseases, in particular of myasthenia gravis. This invention provides novel autoimmune dominant peptides derived from the acetylcholine receptor, as well as methods for preparing the peptides. The present invention further provides complexes comprising these peptides associated with an appropriate major histocompatibility complex (MHC) molecule and methods for making these complexes. The complexes of the present invention can be used therapeutically or prophylactically for treating myasthenia gravis.
Claims25
A MHC Class II peptide complex capable of inducing nonresponsiveness in a target T cell, the complex comprising an antigenic peptide of FIG. 2 bound to an isolated MHC Class II component, said MHC Class II component comprising a β1 domain of a MHC Class II chain and comprising an α1 domain of a MHC Class II chain, and the component comprising an antigen binding pocket, wherein said antigenic peptide is associated with the antigen binding pocket and is recognized by the target T cell.
Dependencies are inferred from the claim text.